Emily Hodges, PA
Physician Assistant · Boerne, TXNPI 1023716693
Payments from drug & device makers
Across 138 payments — averaging $38.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$511
- GSK$407
- AbbVie$341
- Amgen$311
- Novo Nordisk$301
- Nevro Corp.$286
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,264100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 13 | $511 |
| GSK | 15 | $407 |
| AbbVie | 12 | $341 |
| Amgen | 7 | $311 |
| Novo Nordisk | 14 | $301 |
| Nevro Corp. | 2 | $286 |
| Johnson & Johnson | 4 | $278 |
| Axsome Therapeutics, Inc. | 2 | $247 |
| Inspire Medical Systems, Inc. | 6 | $240 |
| Exact Sciences | 12 | $222 |
| AstraZeneca | 3 | $164 |
| Boehringer Ingelheim | 2 | $150 |
| Corcept Therapeutics | 2 | $147 |
| Stryker | 2 | $146 |
| Pfizer | 4 | $144 |
| Intuity Medical Inc | 1 | $142 |
| Bayer | 8 | $132 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Astellas Pharma US Inc | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $124 |
| Dexcom, Inc. | 1 | $122 |
| Kowa Pharmaceuticals America, Inc. | 7 | $118 |
| Organon | 2 | $69 |
| Azurity Pharmaceuticals, Inc. | 3 | $49 |
| Verona Pharma, Inc. | 1 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 1 | $29 |
| Viatris Specialty LLC | 1 | $23 |
| Novartis | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,264 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $52,975 |
| FarxigaDapagliflozin Propanediol | 32 | $35,394 |
| JardianceEmpagliflozin | 15 | $24,707 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $19,043 |
| MounjaroTirzepatide | 15 | $16,686 |
| RybelsusSemaglutide | 11 | $14,111 |
| EliquisApixaban | 11 | $6,326 |
| PaxlovidNirmatrelvir/Ritonavir | 34 | $1,429 |
| Bupropion XlBupropion Hcl | 23 | $1,129 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $1,052 |
| Levothyroxine Sodium | 98 | $1,050 |
| Estradiol | 13 | $1,017 |
| SynthroidLevothyroxine Sodium | 11 | $969 |
| Rosuvastatin Calcium | 78 | $955 |
| Losartan Potassium | 88 | $804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $301 | $67,08752 claims |
| AstraZenecaFarxiga | $164 | $35,39432 claims |
| Boehringer IngelheimJardiance | $150 | $24,70715 claims |
| GSKTrelegy Ellipta | $407 | $19,04319 claims |
| Lilly USA, LLCMounjaro | $511 | $16,68615 claims |
| PfizerEliquis, Paxlovid | $144 | $7,75645 claims |
| AbbVieSynthroid | $341 | $96911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Boerne
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.